William Collier

Mr. Collier is the president and CEO of Arbutus Biopharma, a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients living with chronic hepatitis B infection. He also serves on the company’s Board of Directors. 

Mr. Collier formerly served as president of ViiV Healthcare North America, where he was responsible for business operations in the US and Canada. From the company’s founding in 2009 until 2018, he oversaw the launch of several HIV treatment medications and created the Positive Action Southern Initiative, a community partnership that supports HIV programs for underserved populations in the southern US. 

Previously, Mr. Collier spent several years in senior roles for GlaxoSmithKline in the US, including as senior vice president for sales and senior vice president for marketing analytics and commercial operations. He has also served as area director for GlaxoWellcome’s sub-Saharan African operations based in Johannesburg; as global commercial lead for herpes therapy at Wellcome based in London; and in sales and marketing positions for Abbott Laboratories, SmithKline Beecham and Beecham Pharmaceuticals in the United Kingdom. 

Mr. Collier is a member and governance fellow of the National Association of Corporate Directors (NACD) and a Board member of Genevant. He has also served on President Obama’s Presidential Advisory Council on HIV/AIDS (PACHA) and the Board of Trustees of AIDS United.

He holds a bachelor of science degree in mathematics and management sciences from the University of Manchester in the UK and has completed leadership programs at the London Business School, INSEAD and Duke University.